AVTX
Avalo Therapeutics, Inc.
$19.83
+0.05%
2026-08-21
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Key Fundamentals
Forward P/E
-7.44
EPS (TTM)
$-4.41
ROE
-36.3%
Revenue Growth (YoY)
-69.3%
Profit Margin
0.0%
Debt/Equity
0.05
Price/Book
2.31
Beta
0.79
Market Cap
$1.05B
Avg Volume (10D)
658K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$21.02
60D Low
$12.52
Avg Volume
1.3M
Latest Close
$19.83
Get breakout alerts for AVTX
Sign up for Breakout Scanner to receive daily notifications when AVTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Avalo Therapeutics, Inc. (AVTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AVTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AVTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.